Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Freed From Pfizer, Capsugel May Find More Market Opportunities

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal heightens attention Pfizer is attracting from the investment community, already anticipating divestments outside the firm's innovative core pharma business.

You may also be interested in...



Changes Ahead For Pfizer, But Don't Expect A "Big Bang," Read Says

Pfizer turns in flat first-quarter sales and keeps investors waiting for more details on plans for potential spinouts or restructuring.

Changes Ahead For Pfizer, But Don't Expect A "Big Bang," Read Says

Pfizer turns in flat first-quarter sales and keeps investors waiting for more details on plans for potential spinouts or restructuring.

Sales & Earnings In Brief

NBTY CEO suggests growth trends

Related Content

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel